Compare OII & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | ACAD |
|---|---|---|
| Founded | 1964 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.4B |
| IPO Year | 1994 | 2000 |
| Metric | OII | ACAD |
|---|---|---|
| Price | $40.94 | $20.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 20 |
| Target Price | ★ $41.00 | $30.53 |
| AVG Volume (30 Days) | 958.8K | ★ 1.6M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.36 | 69.12 |
| EPS | ★ 1.53 | 0.20 |
| Revenue | ★ $2,784,156,000.00 | $726,437,000.00 |
| Revenue This Year | $5.62 | $18.71 |
| Revenue Next Year | $3.59 | $12.44 |
| P/E Ratio | ★ $27.14 | $103.78 |
| Revenue Growth | 4.62 | ★ 40.45 |
| 52 Week Low | $22.13 | $18.39 |
| 52 Week High | $54.25 | $30.96 |
| Indicator | OII | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 46.10 |
| Support Level | $34.69 | $20.10 |
| Resistance Level | $53.64 | $22.92 |
| Average True Range (ATR) | 1.85 | 0.59 |
| MACD | -0.03 | 0.39 |
| Stochastic Oscillator | 54.55 | 86.64 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.